Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MC4R | P32245 | 1/20 | 0.36 |
| ▸ | MC5R | P33032 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8554593 | 1.00 | PARP1 (0.43) | PARP1HSD17B10MC4RMC5RSMN1; SMN2 | |
| SCHEMBL17560433 | 1.00 | PARP1 (0.43) | PARP1HSD17B10MC4RMC5RSMN1; SMN2 | |
| SCHEMBL2827159 | 0.88 | PARP1 (0.42) | PARP1HSD17B10MC4RMC5RSMN1; SMN2 | |
| SCHEMBL28704904 | 0.86 | PARP1 (0.44) | PARP1HSD17B10MC4RMC5RSMN1; SMN2 | |
| SCHEMBL18673224 | 0.86 | PARP1 (0.44) | PARP1HSD17B10MC4RMC5RSMN1; SMN2 | |
| SCHEMBL7995550 | 0.86 | PARP1 (0.44) | PARP1HSD17B10MC4RMC5RSMN1; SMN2 | |
| SCHEMBL1685922 | 0.86 | HSD17B10 (0.47) | PARP1HSD17B10MC4RMC5RSMN1; SMN2 | |
| SCHEMBL2480988 | 0.86 | HSD17B10 (0.47) | PARP1HSD17B10MC4RMC5RSMN1; SMN2 | |
| SCHEMBL2480835 | 0.86 | HSD17B10 (0.47) | PARP1HSD17B10MC4RMC5RSMN1; SMN2 | |
| SCHEMBL2584375 | 0.86 | PARP1 (0.44) | PARP1HSD17B10MC4RMC5RSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3654968-B1 | METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-08-16 | — | — | EP | disclosed |
| US-11207312-B2 | Metallo-beta-lactamase inhibitors and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2021-12-28 | — | — | US | disclosed |
| US-20200281913-A1 | Metallo-Beta-Lactamase Inhibitors and Methods of Use Thereof | MERCK SHARP & DOHME CORP. (US) | 2020-09-10 | — | — | US | disclosed |
| EP-3654968-A1 | METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF | Merck Sharp & Dohme Corp. (US) | 2020-05-27 | — | — | EP | disclosed |
| WO-2019018186-A1 | METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. (US) | 2019-01-24 | — | — | WO | disclosed |
| EP-0582164-B1 | Adenosine re-uptake inhibiting derivatives of diphenyl oxazoles, thiazoles and imidazoles | BRISTOL MYERS SQUIBB CO (US) | 1998-12-23 | — | — | EP | disclosed |
| US-5382584-A | Antiischemic agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-01-17 | — | — | US | disclosed |
| EP-0582164-A1 | Adenosine re-uptake inhibiting derivatives of diphenyl oxazoles, thiazoles and imidazoles | Bristol-Myers Squibb Company (US) | 1994-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200281913-A1 | Metallo-Beta-Lactamase Inhibitors and Methods of Use Thereof | MLX, MMP12, SLC11A2 | PARP1 2078/4885HSD17B10 805/4885MC4R 4742/4885 |
| US-11207312-B2 | Metallo-beta-lactamase inhibitors and methods of use thereof | MLX, MMP12, SLC11A2 | PARP1 2078/4885HSD17B10 805/4885MC4R 4742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.